Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Nitesh sinha March 06, 2023
https://ift.tt/lf4yxn5

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review



from Sanofi - Aventis Groupe https://ift.tt/24xDg9L
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link